How much of Atea Pharmaceuticals’ revenue comes from haram?
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics for life-threatening viral infections.
The company’s lead product for treating patients with COVID-19, AT-527, is an orally administered direct-acting antiviral.
Atea earns its revenue primarily through collaboration agreements with Roche.
Practical Islamic Finance concludes:
None of Atea Pharmaceuticals’ revenue comes from anything inherently haram.
Does Atea Pharmaceuticals rely on interest to operate?
|
Most Recent Quarter ended 3/31/2022 |
Fiscal year ended 12/31/2021 |
Fiscal year ended 12/31/2020 |
|
|---|---|---|---|
| Interest Expense | $ | $ | $ |
| Total Operating Expenses | $42,175 | $212,990 | $59,663 |
| Interest Expense / Total Operating Expenses |
0.00% | 0.00% | 0.00% |
Practical Islamic Finance concludes:
Atea Pharmaceuticals, Inc. most recent quarter indicates no reliance on Riba in its operations.
What is Atea Pharmaceuticals’ Environmental, Social, and Governance (ESG) impact?
Environment
No notable environmental highlights.
Social
Atea Pharmaceuticals has a Glassdoor rating of 3.7 out of 5.0 from over 60 current and previous employees compared to a 3.3 average for all other Glassdoor rated companies.
Governance
No notable governance highlights.
Practical Islamic Finance concludes:
Atea Pharmaceuticals has a net positive ESG impact.
Comfort Rating
From Atea Pharmaceuticals’ business, financial, and ESG reviews, Practical Islamic Finance rates Atea Pharmaceuticals stock as:
Comfortable to invest in from a Halal perspective.
Sources
Atea Pharmaceuticals Q2 2021 10-Q
Atea Pharmaceuticals 2020 10-K
